XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Other (Income)/Deductions—Net - Footnotes (Detail) - USD ($)
 3 Months Ended 6 Months Ended
Dec. 14, 2023
Jun. 30, 2024
Mar. 31, 2024
Jul. 02, 2023
Jun. 30, 2024
Jul. 02, 2023
Dec. 31, 2023
May 31, 2023
Loss Contingencies [Line Items]                
Commercial paper, principal amount   $ 7,964,000,000     $ 7,964,000,000   $ 7,965,000,000  
Acquisitions of businesses, net of cash acquired         0 $ 25,000,000    
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date [1]   344,000,000   $ (121,000,000) 533,000,000 363,000,000    
Intangible asset impairment charge         349,000,000      
Seagen [Member]                
Loss Contingencies [Line Items]                
Commercial paper, principal amount             $ 8,000,000,000  
Acquisitions of businesses, net of cash acquired $ 43,400,000,000              
Unsecured Debt [Member]                
Loss Contingencies [Line Items]                
Face amount of debt issued               $ 31,000,000,000
IPR&D [Member]                
Loss Contingencies [Line Items]                
Intangible asset impairment charge [2]         240,000,000      
IPR&D [Member] | Biopharma [Member]                
Loss Contingencies [Line Items]                
Intangible asset impairment charge   240,000,000     240,000,000 128,000,000 [2]    
License Agreements and Other [Member] | Biopharma [Member]                
Loss Contingencies [Line Items]                
Intangible asset impairment charge           120,000,000    
Haleon [Member]                
Loss Contingencies [Line Items]                
Gain on sale of equity method investment     $ 150,000,000   150,000,000      
ViiV [Member]                
Loss Contingencies [Line Items]                
Dividend income         135,000,000 183,000,000    
ViiV [Member] | Biopharma [Member]                
Loss Contingencies [Line Items]                
Dividend income   $ 74,000,000   $ 91,000,000 $ 135,000,000 183,000,000    
Nimbus [Member]                
Loss Contingencies [Line Items]                
Dividend income           $ 211,000,000    
[1] Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of June 30, 2024, there were cumulative impairments and downward adjustments of $306 million and upward adjustments of $214 million. Impairments, downward and upward adjustments were not material to our operations in the second quarters and first six months of 2024 and 2023.
[2] Reflects intangible assets written down to fair value in 2024. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.